Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAetna Medicare Part B preferred drug list | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy N/A

    Medicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    A preferred drug list for medically administered Medicare Part B drugs under Aetna Medicare Advantage (MA) plans, listing preferred and non-preferred Part B drugs by category, HCPCS codes, and links or notes about medical necessity, step therapy, and fax request forms. Affects providers administering Part B drugs to Aetna MA members.

    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred products first and submit the linked medical necessity criteria and fax request form where indicated for each drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipledrug categories
    yesHCPCS codes present
    yesstep therapy noted
    2026-04-01new effective date
    20+
    distinct products listed

    Coverage Criteria and Preferred Product Use

    Preferred product use and exceptions

    General rule

    Preferred-first rule: Preferred products should be used first; an exception process exists for cases that require a non-preferred product.

    Step therapy may be applied; specific step therapy criteria are provided via linked criteria documents.

    Bone resorption inhibitors — initial therapy

    Bone resorption inhibitors

    Tiered requirement: Trial of a first‑tier agent (pamidronate J2430 or zoledronic acid J3489) is required before coverage of second‑tier/non‑preferred bone resorption agents for the listed indications.

    Pamidronate (J2430) and zoledronic acid (J3489) do not require prior authorization; second‑tier products require trial/failure of first‑tier agents and have linked medical necessity/step therapy criteria.

    Botulinum toxins — coverage notes

    Botulinum toxins

    Indications listed: Blepharospasm, cervical dystonia, chronic sialorrhea, and upper limb spasticity are listed indications for botulinum toxin therapy.

    Botox (J0585/J0588) is listed as preferred for these indications with prior authorization not required; other botulinum products (Daxxify J0589, Dysport/Myobloc J0586) are listed with links to criteria or as non‑preferred depending on indication.

    Explicit PA coverage statements

    Coverage statements for listed products (examples):

    Neulasta / Neulasta Onpro coverage: Neulasta and Neulasta Onpro are listed as preferred long‑acting colony stimulating factors and prior authorization is not required.

    See Neulasta entries for PA 'Prior authorization is not required' and 'None' for step therapy.

    Eligard coverage: Eligard (J9217) is listed with medical necessity stating 'Prior authorization is not required.'

    Refer to Eligard line item for PA status.

    Short‑acting G‑CSF coverage: Zarxio is listed as a preferred short‑acting G‑CSF; several other short‑acting G‑CSFs are non‑preferred and reference linked criteria.

    See colony stimulating factors (short‑acting) category.

    Step therapy groups

    Several indications/categories are designated as subject to step therapy:

    Listed indications subject to step therapy: Examples include anemia due to zidovudine use in HIV; transfusion reduction for select surgeries; ulcerative colitis; Crohn's disease; and other listed therapeutic categories—these are marked as 'Indications subject to step therapy'.

    See the specific category entries and linked step therapy criteria for detailed requirements.

    Psoriatic arthritis — formulary placement

    Preferred vs non‑preferred listings and step therapy applicability (as presented)

    Psoriatic arthritis formulary grouping: Preferred drugs include Inflectra (Q5103), Renflexis (Q5104), and Simponi Aria (J1602). Non‑preferred drugs for psoriatic arthritis include Avsola (Q5121), Remicade (J1745)/unbranded infliximab, Cimzia (J0717), and Orencia (J0129).

    Medical necessity and step therapy links are provided per drug line; follow linked criteria for authorization.

    Remicade and biosimilars

    Category: Remicade and biosimilars (all other indications)

    Remicade category: Preferred infliximab biosimilars are Inflectra (Q5103) and Renflexis (Q5104). Non‑preferred products include Avsola (Q5121), Remicade (J1745), and unbranded infliximab.

    Medical necessity and step therapy links are provided for infliximab products; providers should follow those linked criteria.

    IV iron — indications and authorization

    IV iron indications and authorization stance

    IV iron authorization conditions: IV iron is indicated for iron deficiency anemia after intolerance to or unsatisfactory response to oral iron, or for patients with chronic kidney disease.

    Some IV iron products require prior authorization or step therapy (see product lines); sodium ferric gluconate (J2916), Infed (J1750), and Venofer (J1756) are noted as not requiring prior authorization.

    IVIG/SCIG — product listings

    IVIG and SCIG product listing and medical necessity linkage

    IVIG products: Multiple IVIG and SCIG products are listed (e.g., Gammaked/Gamunex‑C J1561, Privigen J1459, Hizentra J1559, Xembify J1558) and each product references linked medical necessity criteria and fax forms as indicated.

    Providers must follow the linked medical necessity criteria and submission instructions for each product.

    Multiple sclerosis / oncology — listings

    MS and oncology infused agents and administrative controls

    MS/oncology agents: Agents such as Ocrevus (J2350), Briumvi (J2329), Lemtrada (J0202), Phesgo (J9316), Perjeta (J9306), and various taxanes are listed with HCPCS codes and linked medical necessity criteria; some require prior authorization (e.g., Docetaxel J9171).

    Step therapy and PA status vary by drug; follow the product‑specific line item and links.

    Per-drug medical necessity and step therapy requirements

    Coverage and authorization depend on drug‑specific medical necessity and step therapy criteria as listed below

    Per‑drug rules: Each drug entry includes the medical necessity status (e.g., 'Link to criteria' or 'Prior authorization is not required'), step therapy status ('None' or link to step therapy criteria), and fax request form instructions. Providers must meet the product‑specific medical necessity and step therapy requirements shown on the drug line item.

    Do not assume uniform rules across drugs; consult the product line for exact requirements.

    Ophthalmic VEGF inhibitors — non-preferred coverage logic

    Covered when product‑specific medical necessity and step therapy requirements are met

    VEGF ophthalmic non‑preferred product coverage: Coverage for a non‑preferred ophthalmic VEGF inhibitor requires prior trial/failure of preferred product(s) from both tiers as stated; product‑specific medical necessity criteria links must be satisfied.

    Preferred product trials from both tiers are required prior to coverage of non‑preferred ophthalmic VEGF agents.

    Prior authorization — product-specific

    Product‑specific prior authorization as listed

    Products requiring prior authorization: Certain product line items (for example, some pemetrexed entries and viscosupplements such as Durolane and Euflexxa) list 'Prior authorization' — authorization is required per the product listing.

    Check the product line for exact PA wording and the required fax request form.

    Product-specific medical necessity and step therapy

    Coverage for viscosupplement products is governed by product‑specific medical necessity and step therapy criteria linked in this document.

    Product-level requirements: Coverage of viscosupplement products (e.g., GenVisc J7320, Hyalgan J7321, Gelsyn‑3 J7328, TriVisc J7329) requires adherence to the product‑specific medical necessity criteria, completion of required step therapy (if applicable), and submission of the required fax request form as indicated.

    Links to medical necessity and fax forms are provided for each viscosupplement line item.

    This document is a Medicare Part B preferred drug list for Aetna Medicare Advantage (MA) plans that groups physician-administered drugs into therapeutic categories and identifies preferred and non-preferred products. The general rule is that the plan prefers use of designated preferred products and may require trial of a preferred agent before covering a non-preferred product; an exception process exists for members who clinically require a non-preferred product. Product-level entries include links or references to medical necessity criteria, step therapy criteria, and fax request forms as applicable, and providers must follow the linked requirements for authorization and documentation.

    Several individual drug entries explicitly state that prior authorization is not required for those products. Examples in the extract include short-acting colony stimulating factors and selected IV iron and oncology agents where the product line shows 'Prior authorization is not required.' Providers should check each product line for the PA designation and follow the provided guidance.

    Certain IV iron products are listed with an explicit operational status of no prior authorization required. Specifically, sodium ferric gluconate (J2916), Infed (J1750), and Venofer (J1756) are shown as not requiring prior authorization in the IV iron category; other IV iron products (e.g., Feraheme, Injectafer, Monoferric) reference step therapy or linked criteria.

    The extract includes multiple examples where the line item indicates "Prior authorization is not required". Examples shown include Paclitaxel (J9267) and Carboplatin (J9045) in their respective categories, as well as several IV iron agents noted above. When a product line states PA is not required, authorization submission is not needed; confirm coding and documentation requirements for billing.

    Ophthalmic anti-VEGF agents are tiered. The policy requires trial of preferred products from both preferred tiers before coverage of a non-preferred ophthalmic VEGF inhibitor. For example, bevacizumab (Avastin) is listed with no PA required in some lines, while non-preferred ophthalmic VEGF agents are restricted until the required preferred-product trials/failures and any product-specific medical necessity criteria are satisfied.

    This extract does not present any discrete clinical exclusions labeled as 'excluded' in the fragments provided. The document notes that full exclusions, limitations, and conditions of coverage are described in the plan Evidence of Coverage or in the linked medical necessity criteria; providers should consult those referenced documents for complete exclusion language.

    Many non-preferred product entries reference a link to medical necessity criteria or list 'Link to criteria' on the product line. Coverage for non-preferred or restricted products is contingent on meeting the referenced product-specific medical necessity criteria, and providers must submit the required documentation and fax request forms where indicated.

    Within the excerpt there are no explicit statements that any drug is categorically 'not medically necessary.' Instead, product lines either reference linked medical necessity criteria or indicate whether prior authorization is required. Clinical determinations of medical necessity are made by applying the linked criteria to the member’s clinical situation.

    Paclitaxel (listed as J9267) appears in the extract with the product line showing that medical necessity criteria / prior authorization is not required for that entry, indicating standard coverage without PA for the scenarios shown in this fragment. Always verify the specific product line for the final PA designation.

    In this extract no agents are explicitly labeled as 'not medically necessary.' Instead, the document repeatedly uses links to the applicable medical necessity criteria for non-preferred products and indicates whether prior authorization or step therapy applies. Final determinations of 'not medically necessary' are made by applying those linked criteria to the individual case.

    Viscosupplement products are listed with product-specific entries that indicate their medical necessity and prior authorization status. For example, the Synvisc line shows "medical necessity is not required" (i.e., prior authorization not required) in the fragment, while other viscosupplements reference links to medical necessity criteria and fax forms. Providers should follow the product-level instructions and submit the referenced fax form when a link to a fax form or PA requirement is shown.

    HCPCS / J-code Listings by Category

    Alpha-1 proteinase inhibitors (preferred)HCPCSCovered
    J0256Prolastin-C, Zemaira (alpha-1 proteinase inhibitors)
    Alpha-1 proteinase inhibitors (non-preferred)HCPCSNot Covered
    J0256Aralast NP (non-preferred listed with same HCPCS in doc)
    J0257Glassia (non-preferred)
    Bone resorption inhibitorsHCPCS
    J3489Zoledronic acid
    J2430Pamidronate
    J0897Prolia / Xgeva (denosumab)
    Q5136Jubbonti / Wyost (example Q-code listed)
    Various osteoporosis and newly effective productsHCPCS
    J3111Evenity
    Q5158Conexxence / Ospomyv / Bomyntra (Q-codes)
    Q5159Ospomyv / Xbryk (Q5159 referenced)
    J3590/C9399Miscellaneous codes used for new products (e.g., Bildyos, Bosaya, Enoby, Osvyrti effective 4/1/2026)
    Botulinum toxinsHCPCSCovered
    J0585Botox
    J0586Dysport / Myobloc (codes mixed in doc)
    J0589Daxxify
    J0588Botox alternate code
    Complement inhibitors / PNH / Neurologic agentsHCPCS
    Q5152Bkemv
    Q5151Epysqli
    J1299Soliris
    J1303Ultomiris / Imaavy
    J1823Uplizna
    J9332Vyvgart
    J9334Vyvgart Hytrulo
    J9333Rystiggo / Epysqli (listed)
    Colony stimulating factors (short-acting)HCPCS
    Q5101Zarxio (preferred colony stimulating factor, short-acting)
    J1447Granix
    J1442Neupogen
    Q5110Nivestym
    Q5148Nypozi
    Q5125Releuko
    J2820Leukine
    Colony stimulating factors (short-acting) codesHCPCS
    Q5101HCPCS code listed under colony stimulating factors (short-acting)
    J1447HCPCS/J-code listed under colony stimulating factors (short-acting)
    J1442HCPCS/J-code listed under colony stimulating factors (short-acting)
    Q5110HCPCS code listed under colony stimulating factors (short-acting)
    Q5148HCPCS code listed under colony stimulating factors (short-acting)
    Q5125HCPCS code listed under colony stimulating factors (short-acting)
    J2820HCPCS/J-code listed under colony stimulating factors (short-acting)
    Colony stimulating factors (long-acting) codesHCPCS
    J2506Neulasta / Neulasta Onpro HCPCS/J-code
    Q5108Fulphila HCPCS code
    Q5130Fylnetra HCPCS code
    Q5122Nyvepria HCPCS code
    Q5127Stimufend HCPCS code
    Q5111Udenyca HCPCS code
    J9361Ryzneuta HCPCS/J-code
    J1449Rolvedon HCPCS/J-code
    Erythropoiesis-stimulating agents and related codesHCPCS
    J0885Procrit / Epogen HCPCS/J-code
    Q5106Retacrit HCPCS code
    J0882Aranesp HCPCS/J-code
    Q4081Procrit alternate HCPCS code
    Q5105Retacrit alternate HCPCS code
    J0901Reblozyl HCPCS/J-code
    Enzyme replacement, factor products, and geographic atrophy agentsHCPCS
    J1786Cerezyme HCPCS/J-code
    J3060Elelyso HCPCS/J-code
    J3385Vpriv HCPCS/J-code
    J7211Kovaltry HCPCS/J-code
    J7209Nuwiq HCPCS/J-code
    J7182NovoEight HCPCS/J-code
    J7185Xyntha HCPCS/J-code
    J2782Izervay HCPCS/J-code
    J2781Syfovre HCPCS/J-code
    Hormone therapy and biologics (IBD/other) codesHCPCS
    J9217Eligard HCPCS/J-code
    J1950Lupron depot HCPCS/J-code
    J3315Trelstar HCPCS/J-code
    J9202Zoladex HCPCS/J-code
    J9155Firmagon HCPCS/J-code
    J3380Entyvio IV HCPCS/J-code
    Q5103Inflectra HCPCS code
    Q5104Renflexis HCPCS code
    Q9997Pyzchiva IV HCPCS code
    Q5100Yesintek IV HCPCS code
    1–10 of 12
    1/2
    Additional biologic HCPCS/J-codes (IBD and others)HCPCS
    Q5098Imuldosa IV HCPCS code
    Q9999Otulfi IV HCPCS code
    Q9998Selarsdi IV HCPCS code
    J3590Starjemza IV HCPCS/J-code
    J3358Stelara IV HCPCS/J-code
    Q5099Steqeyma IV HCPCS code
    Q5138Wezlana IV HCPCS code
    J0717Cimzia HCPCS/J-code
    J2323Tysabri HCPCS/J-code
    Drugs listed under Crohn's diseaseHCPCS
    J1745Remicade; Unbranded infliximab (HCPCS code listed for infliximab products)
    J0717Cimzia
    Q5098Imuldosa IV
    Q9999Otulfi IV
    Q9998Selarsdi IV
    J3590Starjemza IV (misc. code J3590 used)
    J3358Stelara IV
    Q5099Steqeyma IV
    Additional Crohn's disease / related biologicsHCPCS
    Q5138Wezlana IV
    Q5134Tyruko
    J2323Tysabri
    Drugs listed under PsoriasisHCPCS
    Q5103Inflectra
    Q5104Renflexis
    Q5121Avsola
    J3245Ilumya
    Drugs listed under Rheumatoid arthritisHCPCS
    J1602Simponi Aria
    J0129Orencia
    Q5123Riabni
    J9312Rituxan
    Q5119Ruxience
    Q5115Truxima
    IV iron productsHCPCS
    J2916Sodium ferric gluconate
    J1750Infed
    J1756Venofer
    Q0139Feraheme (misc codes listed Q0139/Q0138)
    Q0138Feraheme (misc codes listed Q0139/Q0138)
    J1439Injectafer
    J1437Monoferric
    IVIG and SCIG productsHCPCS
    J1561Gammaked / Gamunex-C (IVIG/SCIG listings)
    J1459Privigen
    J1552Alyglo
    J1554Asceniv
    J1556Bivigam
    J1572Flebogamma
    J1569Gammagard S/D
    J1568Gammaplex
    J1576Panzyga
    J3590Yimmugo (misc codes J3590/C9399)
    1–10 of 16
    1/2
    Multiple sclerosis and oncology-related infused agentsHCPCS
    J2350Ocrevus
    J2351Ocrevus Zunovo
    J2329Briumvi
    J0202Lemtrada
    J9316Phesgo
    J9306Perjeta
    J9171Docetaxel
    J9267Paclitaxel
    J9264Abraxane / paclitaxel (protein-bound)
    Selected HCPCS codes (examples)HCPCS
    J9316Phesgo
    J9306Perjeta
    Taxane group HCPCSHCPCS
    J9171Docetaxel
    J9267Paclitaxel
    J9264Abraxane / Paclitaxel (protein-bound)
    Bevacizumab and biosimilarsHCPCS
    Q5107Mvasi
    Q5118Zirabev
    J9035Avastin
    PD1/PDL1 HCPCSHCPCS
    J9119Libtayo
    J9271Keytruda
    J9299Opdivo
    J9289Opdivo Qvantig
    Pemetrexed and related codesHCPCS
    J9305Pemetrexed / Alimta group (as shown)
    J9294Other pembrolizumab/related misc codes listed
    Pemetrexed and misc HCPCSHCPCS
    J9119HCPCS code listed under Pemetrexed category
    J9271HCPCS code listed under Pemetrexed category
    J9299HCPCS code listed under Pemetrexed category
    J9289HCPCS code listed under Pemetrexed category
    J3590/C9399Misc codes referenced (multiple products)
    J9305HCPCS code listed
    J9294HCPCS code listed
    J9296HCPCS code listed
    J9297HCPCS code listed
    J9314HCPCS code listed
    Ophthalmic VEGF inhibitor HCPCSHCPCS
    Q5124Byooviz HCPCS code
    J0178Eylea HCPCS code
    J0177Eylea HD HCPCS code
    Q5147Pavblu HCPCS code
    Q5150Ahzantive HCPCS code
    Q5149Enzeevu HCPCS code
    Q5153Opuviz HCPCS code
    Q5155Yesafili HCPCS code
    J0179Beovu HCPCS code
    Q5128Cimerli HCPCS code
    1–10 of 13
    1/2
    Viscosupplements HCPCSHCPCS
    J7318Durolane HCPCS code (viscosupplement)
    J7325Synvisc-one / Synvisc HCPCS code
    J7326Gel-one HCPCS code
    J7327Monovisc HCPCS code
    J7322Hymovis One HCPCS code (effective 4/1/2026)
    J7323Euflexxa HCPCS code
    Miscellaneous HCPCS/j codesHCPCS
    J3590/C9399Misc codes referenced for Keytruda Qlex and Eydenzelt
    Viscosupplement HCPCS codesHCPCS
    J7320GenVisc (HCPCS code as listed)
    J7321Hyalgan; Supartz FX; Visco-3 (HCPCS code as listed)
    J7322Hymovis (HCPCS code as listed)
    J7323Euflexxa (HCPCS code as listed)
    J7324Orthovisc (HCPCS code as listed)
    J7325Synvisc (HCPCS code as listed)
    J7328Gelsyn-3 (HCPCS code as listed)
    J7329TriVisc (HCPCS code as listed)
    J7331Synojoynt (HCPCS code as listed)
    J7332Triluron (HCPCS code as listed)
    Step therapy examples
    Examples of indications subject to step therapyAnemia due to Zidovudine use in HIV; transfusion reduction for select surgeries.

    Prior Authorization, Step Therapy, and Submission Requirements

    Prior Authorization

    Prior authorization expectations

    Prior authorization expectations: Requirements vary by drug and indication. Some products (including many IV and specialty agents) require prior authorization before administration; others explicitly state “prior authorization is not required.” When PA is required, providers must follow the associated medical-necessity criteria and submit the specified fax request form or electronic request as noted on Aetna’s criteria pages.

    • Check the product-specific entry for PA status (e.g., “Prior authorization is not required” vs. “Prior authorization”).
    • If PA is required, use the linked medical necessity criteria and the listed fax request form.
    Prior Authorization

    Prior authorization varies by drug

    Prior authorization varies by drug and product class. Examples in this document show that some short-acting and long-acting colony stimulating factors, certain bisphosphonates, carboplatin, select oncology agents, and many ophthalmic VEGF inhibitors have mixed PA status across preferred vs non-preferred products.

    • Always verify the HCPCS/NDC-level entry for the specific product (preferred vs non-preferred).

    Initial Therapy Preferences and Authorization

    Bone resorption — initial therapy

    First‑line preferred agents for bone resorption indications

    First‑tier trial: Trial of pamidronate (J2430) or zoledronic acid (J3489) is required before second‑tier/non‑preferred bone resorption agents will be covered for the listed indications.

    Pamidronate and zoledronic acid are first‑tier preferred agents and do not require prior authorization.

    Initial therapy preferences

    Preferred vs non‑preferred listing and prior authorization expectations

    Preferred short‑acting and long‑acting G‑CSF: Zarxio (Q5101) is listed as a preferred short‑acting colony stimulating factor; Neulasta and Neulasta Onpro (J2506) are listed as preferred long‑acting agents with 'Prior authorization is not required.' Non‑preferred G‑CSFs reference linked criteria for medical necessity and step therapy.

    Follow the specific drug line for PA and step therapy status.

    Step Therapy Rules and Required Trials

    RuleNotes / source
    Preferred-first step therapy
    Preferred products should be used prior to non-preferred products; an exception process exists for cases requiring a non-preferred product. Specific step therapy criteria are provided via linked criteria documents.
    Example agent / indicationStep therapy note
    Anemia due to Zidovudine use (Procrit preferred / Epogen non-preferred)
    Ulcerative colitis (Entyvio, Inflectra, Renflexis listed; step therapy criteria: None for listed preferred biologics)
    Iron deficiency anemia (IV iron) — after intolerance to oral iron or CKD; some IV iron products (e.g., sodium ferric gluconate J2916, Infed J1750, Venofer J1756) have 'Prior authorization is not required' while others reference step therapy criteria.
    Drug / categoryStep therapy linkage / per-drug note
    Psoriatic arthritis — Inflectra, Renflexis, Simponi Aria (preferred) vs Avsola, Remicade, Cimzia, Orencia (non-preferred)
    Remicade and biosimilars — Inflectra (Q5103) and Renflexis (Q5104) listed as preferred alternatives; Remicade (J1745) listed as non-preferred with links to medical necessity/step therapy.
    IV iron — multiple products listed with product-specific notes; some require step therapy criteria (e.g., Feraheme, Injectafer, Monoferric) and others do not.
    MS / oncology infused agents (e.g., Phesgo, Perjeta, Docetaxel) — step therapy status varies by product; per-drug medical necessity and step therapy links provided.
    ProductStep therapy status
    Inflectra (Q5103)
    Neulasta / Neulasta Onpro (long-acting G-CSF) — preferred listing; per-line shows 'Prior authorization is not required' for some agents
    Docetaxel (J9171) — medical necessity: Prior authorization; step therapy: per product listing
    RequirementDetails / example
    Tiered preferred-product trial required
    For certain categories (e.g., bone resorption inhibitors), trial of first-tier preferred agents (pamidronate J2430 or zoledronic acid J3489) is required before second-tier or non-preferred agents are covered; pamidronate and zoledronic acid do not require prior authorization.
    VEGF/ophthalmic ruleCoverage implication
    Preferred products from both tiers required before non-preferred ophthalmic VEGF inhibitor
    Coverage for a non-preferred ophthalmic VEGF inhibitor requires prior trial/failure of preferred product(s) from both tiers; product-specific medical necessity criteria and step therapy links must be satisfied (examples: Bevacizumab/Avastin, Eylea, Byooviz listed with tiered preferred requirements).

    Administration and Infusion Settings

    Note

    Infusion center — implied site‑of‑care

    Infused biologics are listed with HCPCS/J‑codes implying administration in infusion settings (infusion center); providers should bill and document administration in the appropriate setting.

    • Entries for infused biologics include HCPCS/J‑codes and linked criteria (e.g., Inflectra Q5103, Renflexis Q5104, Entyvio J3380).
    • Site‑of‑care restrictions are not detailed in this fragment but infusion administration is implied.

    Biosimilar Preferences and Related Notes

    Billing Rule

    Neupogen — non‑preferred; Zarxio preferred

    Zarxio is listed as the preferred short‑acting G‑CSF while Neupogen is listed as non‑preferred; follow the formulary preference and linked criteria when selecting agents.

    • Zarxio: listed as preferred (HCPCS Q5101).
    • Neupogen and other short‑acting G‑CSFs are listed as non‑preferred with links to criteria.
    Billing Rule

    Remicade / unbranded infliximab — linked criteria

    Remicade and unbranded infliximab are listed with linked medical necessity and step therapy criteria; biosimilars are shown as preferred alternatives in many categories—use the listed HCPCS/J‑codes and linked criteria when requesting coverage.

    • Remicade (J1745) and unbranded infliximab list “Link to criteria” and step therapy instructions.

    Definitions and Category Notes

    Preferred product
    DefinitionA drug the plan prefers and may require be tried first under step therapy before covering a non-preferred product.
    Operational effectPreferred products should be used first; an exception process exists for cases requiring a non-preferred product.
    Where to find criteriaSpecific medical indications subject to step therapy are detailed in the corresponding step therapy criteria documents linked on Aetna's website.
    Colony stimulating factors (short-acting)
    Class descriptionTherapies to stimulate neutrophil production; includes short-acting G-CSF agents with preferred and non-preferred listings.
    Preferred product exampleZarxio (preferred short-acting G-CSF, HCPCS Q5101).

    Background and Scope

    The document groups Medicare Part B administered drugs into categories and identifies preferred and non-preferred products for Aetna MA plans. It emphasizes that coverage decisions for many listed products depend on meeting the linked medical necessity criteria and any applicable step therapy rules; providers are directed to the linked criteria and fax forms for each product and to the plan Evidence of Coverage for full benefit details.

    Policy Revision History

    2025copyrightLatest

    Document footer shows copyright year 2025.

    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred products first and submit the linked medical necessity criteria and fax request form where indicated for each drug.
    SourceLink
    On This Page
    Coverage Criteria and Preferred Product UseHCPCS / J-code Listings by CategoryPrior Authorization, Step Therapy, and Submission RequirementsInitial Therapy Preferences and AuthorizationStep Therapy Rules and Required TrialsAdministration and Infusion SettingsBiosimilar Preferences and Related NotesDefinitions and Category NotesBackground and ScopePolicy Revision History
    Preferred product requirementPreferred drugs (e.g., Procrit for listed anemia indications) should be tried first before non-preferred alternatives.
    Step therapy documentationProduct lines include links to step therapy criteria and fax request forms where applicable; follow linked criteria per drug.
    Oral iron intolerance / CKD
    Indication specificsIV iron indicated after intolerance to oral iron or unsatisfactory response to oral iron, or in patients with chronic kidney disease.
    Coverage linkageMedical necessity criteria for IV iron products are linked per product; follow product-specific criteria.
    Step therapy / PA notesSome IV iron products show 'None' for step therapy while others reference step therapy criteria or require prior authorization; check the product line.
  1. Preferred products often have no PA; non-preferred products are more likely to require PA.
  2. Prior Authorization

    Prior authorization requirement (product-specific)

    Product-specific prior authorization requirements: follow the line-item entry for each drug. The policy lists PA status and provides a link to medical necessity criteria and a fax request form where applicable.

    • Examples: • Zoledronic acid (J3489) — prior authorization is not required. • Carboplatin (J9045) — prior authorization is not required. • Docetaxel (J9171) — prior authorization required. • Durolane (J7318) — prior authorization required. • Euflexxa (J7323) — prior authorization required.
    • When a product is effective-dated (e.g., new HCPCS or misc codes effective 4/1/2026), check the posted criteria on the effective date.
    Prior Authorization

    Prior authorization requirement for viscosupplements

    Viscosupplements: PA and documentation requirements differ by product and by single- vs multiple-injection formulations. Several viscosupplements require prior authorization and the associated fax form; others do not.

    • Single-injection products (examples): Durolane (J7318) — PA required; Synvisc-one (J7325) — PA not required.
    • Multiple-injection products (examples): Euflexxa (J7323) — PA required; Synvisc (J7325) — PA not required.
    • Use the product entry to locate the linked medical necessity criteria and the fax request form.
    Step Therapy

    Step therapy requirement

    Step therapy requirement: Many drug classes use step therapy — providers must try preferred products first (tiered preferred requirements) before a non-preferred agent will be covered. An exceptions process exists for clinical situations that justify bypassing the step.

    • Step therapy applies to multiple classes (e.g., VEGF inhibitors, bone resorption inhibitors, select biologics).
    • Preferred-product trial from one or both tiers may be required prior to non-preferred coverage.
    • Providers may request an exception when medically necessary; follow the documented exception process on Aetna’s site.
    Step Therapy

    Step therapy applicability

    Step therapy applicability and examples: the policy identifies indications that are subject to step therapy and links to the specific step therapy criteria for each product or indication.

    • Examples of indications subject to step therapy include: osteoporosis, psoriatic arthritis, ulcerative colitis, iron deficiency anemia (after oral iron trial or intolerance), certain oncology indications, and ophthalmic VEGF use.
    • For many biosimilars and infliximab products, preferred biosimilars are listed and step therapy may require trial of preferred biosimilars before non-preferred originator or non-preferred biosimilars.
    Step Therapy

    Step therapy requirements for VEGF inhibitors

    Step therapy requirements for VEGF inhibitors (ophthalmic): Preferred products from both tiers may be required before a non-preferred VEGF inhibitor will be approved. Providers should confirm whether a preferred-product trial is mandated for the patient’s indication.

    • Bevacizumab (Avastin) for ophthalmic use is listed as preferred in many cases and often does not require PA.
    • Non-preferred ophthalmic VEGF agents may require documentation of trial/failure of preferred products and submission of the fax request form.
    Denial Risk

    Denial triggers (inferred)

    Denial triggers and denial risk: Requests missing required documentation, lacking evidence of step-therapy trial (when applicable), or for non-preferred products with no documented exception are at higher risk for denial.

    • Common denial triggers: absent or incomplete medical necessity documentation, failure to document prior trial of preferred product when step therapy applies, and submission without the required fax form or criteria reference.
    • Non-preferred products commonly carry higher PA/denial risk if preferred alternatives were not tried or an exception was not justified.
    Documentation Required

    Submission documentation

    Submission documentation: Providers must submit product-specific medical necessity documentation and the designated fax request form (or follow the electronic submission process) and reference the linked criteria in the request.

    • Include clinical history, prior therapies and responses, relevant lab/imaging results, and rationale for using a non-preferred product if applicable.
    • Reference the exact Aetna medical necessity criteria link shown in the policy entry; attach or fax the product-specific request form listed on the same entry.
    Documentation Required

    Provide linked criteria and fax form

    Provide linked criteria and fax form: When the drug entry includes a link to medical necessity criteria and a fax request form, providers must supply both in the PA submission to avoid processing delays.

    • Locate the criteria and fax form links in the drug’s line-item entry on the Part B preferred drug list.
    • If the entry states “Prior authorization is not required,” no fax form is necessary; otherwise submit the listed form.
    Documentation Required

    Submit product-specific medical necessity and fax form

    Submit product-specific medical necessity documentation and fax form: Use the product’s HCPCS and the policy’s specified fax request form. For products with effective-dated updates, submit the form and supporting documentation consistent with the effective date and posted criteria.

    • When submitting, include HCPCS code, diagnosis, prior treatment(s), dates, and justification for the requested drug.
    • For newly added products (e.g., entries effective 4/1/2026), check that the criteria and form are posted before submitting or follow the guidance to submit on/after the effective date.

    Initial therapy authorization

    Initial coverage actions referenced

    Initial authorization actions: For initial use of listed viscosupplement products, providers must follow linked step therapy and medical necessity criteria and submit the referenced fax request form where indicated.

    Some viscosupplement products are noted as prior authorization not required (e.g., Synvisc in the fragment); verify the product line item.

  3. Inflectra (Q5103) and Renflexis (Q5104) are preferred alternatives per multiple category listings.
  4. Billing Rule

    Remicade (J1745) — preferred biosimilar alternatives

    Inflectra (Q5103) and Renflexis (Q5104) are listed as preferred alternatives to Remicade (J1745) in multiple categories; when applicable, select preferred biosimilars first and follow the linked criteria for coverage.

    • Inflectra Q5103 and Renflexis Q5104: listed as preferred in psoriatic arthritis and other categories.
    • Remicade (J1745) shown as non‑preferred in those groupings with “Link to criteria.”
    Billing Rule

    Mvasi (Q5107) — Avastin biosimilar listing

    Mvasi (Q5107) is listed with a link to medical necessity criteria and appears as a preferred bevacizumab biosimilar in some oncology entries; follow the linked criteria and use the listed HCPCS codes when requesting coverage.

    • Mvasi (Q5107): “Medical necessity criteria = Link to criteria” and “Fax request form = Link to fax form.”
    • Preferred biosimilar status is shown in bevacizumab/biosimilar groupings—use the product’s HCPCS Q‑code when billing.
    Billing Rule

    Bevacizumab/ophthalmic biosimilars — trial preferred first

    Ophthalmic bevacizumab biosimilars and other VEGF agents are tiered; preferred agents (including listed biosimilars) must be trialed prior to non‑preferred products—follow the product HCPCS/Q‑codes and linked medical necessity.

    • Byooviz (Q5124), Eylea (J0178), Beovu (J0179), Cimerli (Q5128), Lucentis (J2779) listed with “Preferred product from both tiers required prior to receiving a non‑preferred product.”
    • Medical necessity links and fax forms are provided per product.
    Non-preferred examplesGranix, Neupogen, Nivestym, Nypozi, Releuko, Leukine (listed non-preferred short-acting agents).
    Colony stimulating factors (long-acting)
    Class descriptionLong-acting pegylated or sustained-release G-CSF agents and biosimilars with HCPCS/J-codes and product-specific criteria.
    Preferred examples (no PA)Neulasta / Neulasta Onpro (J2506) — prior authorization is not required and step therapy = None.
    Non-preferred/alternativesFulphila (Q5108), Fylnetra (Q5130), Nyvepria (Q5122), Stimufend (Q5127), Udenyca (Q5111) — many reference links to step therapy or fax forms.
    Category: IVIG (intravenous immunoglobulin)
    CategoryIntravenous immunoglobulin (IVIG) products listed with HCPCS codes and product-level medical necessity links.
    Examples of listed IVIGsGammaked (J1561), Gamunex-C (J1561), Privigen (J1459), Alyglo (J1552), Asceniv (J1554).
    Documentation requirementMedical necessity criteria and fax request forms are provided per IVIG product; follow linked criteria.
    Category: SCIG (subcutaneous immunoglobulin)
    CategorySubcutaneous immunoglobulin (SCIG) products listed with HCPCS codes and product-level medical necessity links.
    Examples of listed SCIGsHizentra (J1559), Xembify (J1558), Cutaquig, Cuvitru — entries include links to medical necessity and fax forms.
    Authorization notesMany SCIG entries show 'None' for step therapy but require adherence to linked medical necessity criteria and fax forms as specified.
    Category: PD1/PDL1
    Class descriptionImmune checkpoint inhibitors targeting PD‑1/PD‑L1 used for oncology indications (entries list preferred and non-preferred agents with HCPCS codes).
    Preferred vs non-preferred examplePreferred: Libtayo (J9119). Non-preferred: Keytruda (J9271), Opdivo (J9299) and related Q/misc codes.
    Step therapy/indicationsCertain indications (e.g., squamous cell carcinoma, unresectable/metastatic colon or rectal cancer) are noted as subject to step therapy; check linked criteria per product.
    On-label oncology indications (examples)
    On-label oncology examplesUnresectable, inoperable, or metastatic colon cancer; metastatic rectal cancer are cited as on-label indications in the immunotherapy references.
    Use guidancePreferred and non-preferred PD‑1/PD‑L1 agents are listed by indication; follow product-specific medical necessity links for coverage rules.
    Step therapy noteSome immunotherapy entries reference step therapy or 'Link to criteria' for specific oncologic indications; verify per drug line.
    Viscosupplements (multiple injection)
    DefinitionViscosupplements (multiple injection): injectable hyaluronic acid products for joint use listed with HCPCS codes and linked medical necessity/step therapy criteria.
    Examples and codesGelsyn-3 (J7328), GenVisc (J7320), Hyalgan (J7321), Hymovis (J7322), Orthovisc (J7324), Synojoynt (J7331), Triluron (J7332), TriVisc (J7329), Supartz FX (J7321).
    Authorization requirementCoverage requires adherence to product-specific medical necessity criteria and completion of required step therapy/fax submission as indicated.
    VEGF inhibitors (ophthalmic)
    Category descriptionOphthalmic VEGF inhibitors are tiered anti‑VEGF agents for ocular use; preferred products from both tiers must be tried before non-preferred products.
    Preferred-product trial requirementNon-preferred ophthalmic VEGF inhibitors require prior trial/failure of preferred products from both tiers prior to coverage.
    Examples of HCPCS-listed agentsEylea (J0178/J0177), Beovu (J0179), Lucentis / Susvimo (J2779), Vabysmo (J2777), biosimilars such as Byooviz (Q5124), Cimerli (Q5128).